C
Cellibre
Turns cells into specialized, sustainable factories for the manufacture of globally significant products at scale
About Cellibre
Cellibre operates in the biomanufacturing sector, focusing on the sustainable production of cannabinoid ingredients through advanced cellular engineering. The company serves pharmaceutical, wellness, and consumer goods industries by providing high-quality, cost-effective cannabinoid compounds. Cellibre leverages fermentation technology to move production from traditional agricultural methods to controlled environments, enhancing efficiency and reducing environmental impact. The business model revolves around licensing its proprietary technology and selling the produced cannabinoids to various clients. Revenue is generated through technology licensing fees and direct sales of cannabinoid products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- San Diego, United States
- Employees
- 26
- Open positions
- 1
- Dealroom signal
- 63.6/100
- Industry
- Health, Food
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Fermentation, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Cellibre.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2025 | $0 | — | Symrise | ↗ |
| GRANT✓Other financing | Jun 2024 | $2M | — | National Institutes of Health | ↗ |
Growth signals
Latest recorded traffic for Cellibre is 1.1K monthly website visits, up 243.8% over the last three months. Cellibre's team grew 4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A7 investors entered at this stage
- MPMerida Capital Partners
Scott Gordon- DVDelta Emerald Ventures
Entourage Effect Capital
L2 Ventures
Flatiron Venture Partners
Symrise
Other known investors5 additional known investors
Alumni Ventures
Archytas Ventures
Arcview Ventures
Beresford Ventures
Towerview Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cellibre on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cellibre’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







